의약품 급여 결정과 다기준의사결정(Multiple Criteria Decision Analysis) 활용에 대한 고찰

참고문헌 (58)

1. Tsourapas A, "Evaluating ‘success’ in programme budgeting and marginal analysis: a literature review", J Health Serv Res Policy, 16, pp.177~183 (2011)
2. "Health expenditure per capita. In: Health at a Glance 2009. OECD Indicators"[URL]
3. Simoens S, "Health technologies for rare diseases: does conventional HTA still apply?", Expert Rev Pharmacoecon Outcomes Res, 14, pp.315~317 (2014)
4. Marsh K, "Assessing the value of healthcare interventions using multi-criteria decision analysis: a review of the literature", Pharmacoeconomics, 32, pp.345~365 (2014)
5. Dionne F, "The challenge of obtaining information necessary for multi-criteria decision analysis implementation: the case of physiotherapy services in Canada", Cost Eff Resour Alloc, 11, pp.11~ (2013)
6. Baltussen R, "Priority setting of health interventions: the need for multi-criteria decision analysis", Cost Eff Resour Alloc, 4, pp.14~ (2006)
7. "Briefing paper for methods review workshop on structured decision making" (2012)[URL]
8. "Life Saving Drugs Programme Review: Technical Assessment" (2015)[URL]
9. "Ontario Public Drug Programs (OPDP) Evaluation Framework for Drugs for Rare Diseases (DRDs)" (2010)[URL]
10. Annemans L, "Current methodological issues in the economic assessment of personalized medicine", Value Health, 16(6 Suppl), pp.S20~S26 (2013)
11. Simoens S, "How to assess the value of medicines?", Front Pharmacol, 1, pp.115~ (2010)
12. Peacock SJ, "Priority setting in health care using multi-attribute utility theory and programme budgeting and marginal analysis (PBMA)", Soc Sci Med, 64, pp.897~910 (2007)
13. Thokala P, "Multiple criteria decision analysis for health technology assessment", Value Health, 8, pp.1172~1181 (2012)
14. Wagner M, "Methodological development of a comprehensive MCDA framework based on real life issues in appraisal of treatments for rare diseases", Health Technology Assessment International (HTAi) 11th Annual Conference (2014)
15. Linkov I, "Comparative risk assessment and environmental decision making", pp.15~54 (2004), Kluwer
16. Sustainability of electricity supply technologies under German conditions: a comparative evaluation, "Hirschberg, S", Paul Scherrer Institut, ~, pp.PSI Report No. 04-15 (2004)
17. McDaniel C, "Marketing Research Essentials" (2005), John Wiley & Sons Inc
18. A conceptual and methodological framework for value assessment of medical technologies using MCDA, "Angelis A", Health Technology Assessment international, ~ (2014)
19. Diaby V, "How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide", Expert Rev Pharmacoecon Outcomes Res, 14, pp.81~99 (2014)
20. Goetghebeur MM, "Evidence and Value: Impact on DEcisionMaking--the EVIDEM framework and potential applications", BMC Health ServRes, 8, pp.270~ (2008)
21. "HTA Core Model Application for Pharmaceuticals (2.1). Eunetha HTA Core Model Online"[URL]
22. Ramli A, "National Drug Formulary review of statin therapeutic group using the multiattribute scoring tool", Ther Clin Risk Manag, 9, pp.491~504 (2013)
23. Youngkong S, "Multicriteria decision analysis for including health interventions in the universal health coverage benefit package in Thailand", Value Health, 15, pp.961~970 (2012)
24. Tony M, "Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada", BMC Health Serv Res, 11, pp.329~ (2011)
25. Goetghebeur MM, "Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients", Cost Eff Resour Alloc, 8, pp.4~ (2010)
26. Miot J, "Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa", Cost Eff Resour Alloc, 10, pp.2~ (2012)
27. Dionne F, "Developing a multi-criteria approach for drug reimbursement decision making: an initial step forward", J Popul Ther Clin Pharmacol, 22, pp.e68~e77 (2015)
28. Tervonen T, "Applying Multiple Criteria Decision Analysis to Comparative Benefit-Risk Assessment: Choosing among Statins in Primary Prevention", Med Decis Making, 35, pp.859~871 (2015)
29. Diaby V, "An application of a proposed framework for formulary listing in low-income countries: the case of Côte d’Ivoire", Appl Health Econ Health Policy, 9, pp.389~402 (2011)
30. Hummel MJ, "Using the analytic hierarchy process to elicit patient preferences: prioritizing multiple outcome measures of antidepressant drug treatment", Patient, 5, pp.225~237 (2012)
31. Danner M, "Integrating patients’ views into health technology assessment: Analytic hierarchy process (AHP) as a method to elicit patient preferences", Int J Technol Assess Health Care, 27, pp.369~375 (2011)
32. Hsu JC, "Net clinical benefit of oral anticoagulants: a multiple criteria decision analysis", PLoS One, 10, pp.e0124806~ (2015)
33. Health Insurance Review & Assessment Service, "Regulation for evaluation criteria and procedures, etc. for reimbursement eligibility, etc. of drugs (HIRA Regulation No. 263, 2015 May 29)", Health Insurance Review & Assessment Service, ~ (2015)
34. Health Insurance Review & Assessment Service, "Detailed evaluation criteria for drugs subject to negotiation including new drugs, etc", Health Insurance Review & Assessment Service, ~ (2015)
35. "Interim Process and Methods of the Highly Specialised Technologies Programm" (2013)[URL]
36. "The Pharmaceutical Price Regulation Scheme 2014"[URL]
37. "Guidance to support operation of the CDF in 2015-16" (2015)[URL]
38. Cooper C, "NHS cuts to drugs fund mean thousands of cancer patients in England will be denied life-extending treatments", The Independent, ~ (2015)
39. "Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. Version 4.4" (2013)[URL]
40. "Ontario Public Drug Programs"[URL]
41. "New Drug Funding Program (NDFP)"[URL]
42. "Evidence Building Program (EBP)"[URL]
43. "Case-by-Case Review Program"[URL]
44. "Drugs Reimbursement Evaluation Committee final recommendation"[URL]
45. "Published technology appraisals"[URL]
46. "Summary Documents by Product"[URL]
47. "CADTH Common Drug Review (CDR) Reports"[URL]
48. "ADTH pan-Canadian Oncology Drug (pCODR) Review"[URL]
49. Health Insurance Review & Assessment Service, "The Guidelines for Pharmaceutical Economic Evaluation", Health Insurance Review & Assessment Service, ~ (2012)
50. Ministry of Health and Welfare, "Press release. Insurance to cover costs for maintaining complete dentures for the elderly beginning October 1st, and pilot project for a refund system to be extended for 3 more years", ~ (2012)
51. Ministry of Health and Welfare, "Press release. Further discussion on scaling up the refund system within 2 months", ~ (2012)
52. "Drugs Reimbursement Evaluation Committee final recommendation"[URL]
53. "Guide to the Methods of Technology Appraisal 2013"[URL]
54. "Eculi zumab for treating atypical haemolytic uraemic syndrome. Highly specialised technology guidance" (2015)[URL]
55. Incorporating Multiple Criteria in HTA: Methods and Processes, "Devlin NJ", Office of Health Economics, ~ (2011)
56. "How cancer drug funding decisions are made" (2013)[URL]
57. Hongoh V, "Spatially explicit multi-criteria decision analysis for managing vector-borne diseases", Int J Health Geogr, 10, pp.70~ (2011)
58. Ed Waddingham, "A Bayesian approach to probabilistic sensitivity analysis in structured benefit-risk assessment", Biometrical Journal, 58(1), pp.28~42 (2016), Wiley[DOI]

관련 논문AI추천